Impact of Iron Deficiency and Its Correction on Mitochondrial Metabolism of the Cardiomyocyte (MitoCardioFer) (MitoCardioFer)
Iron-deficiency, Valvular Heart Disease
About this trial
This is an interventional basic science trial for Iron-deficiency focused on measuring ferric carboxymaltose, mitochondrial metabolism, cardiomyocyte
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- Patients that must be operated for a valvular heart surgery (aortic or mitral) scheduled in the month which follows the anaesthesia consultation (visit of inclusion)
- The preoperative iron status is known
- Patient signed informed consent
Exclusion Criteria:
- Refusal of the patient to participate
- Refusal of the surgeon or the anaesthetist who are responsible of patient management
- Patients with a known iron overload (for example : hemochromatosis)
- Counter-indication in the realization of a sternal bone marrow biopsy or myocardial biopsy (for example : endocarditis)
- Adult patients under legal guardianship
- Pregnancy
Sites / Locations
- CHU Angers - DEPARTEMENT D'ANESTHESIE REANIMATION
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Other
Control group
Iron deficiency group
Iron treated group
Patients with no iron deficiency prior to inclusion and who did not receive intravenous iron prior to inclusion. Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)
Patients with iron deficiency who did not receive intravenous iron prior to inclusion. Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)
Patients with iron deficiency who received intravenous iron prior to inclusion (greater than or equal to 1 g ferric carboxymaltose). Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)